Page 36 - IMO-1-1

Innovative Medicines & Omics Antioxidant nanomedicines for therapies

have been used for mitigating macular oxidative stress, but last for 56 days, owing to the sustained release of resveratrol
till now they have not been approved for AMD treatment antioxidant from the nanomedicine.
due to low efficacy. 361 The antioxidative effect of intravitreally administrated
Antioxidant nanomedicines have provided new antioxidant nanomedicines should be long-lasting and
approaches for scavenging macular ROS. Luo et al. sustainable to remove the need for multiple intravitreal
prepared a poly(catechin) antioxidant-based composite injection and eye puncture. Therefore, antioxidant
nanomedicine, which was demonstrated to alleviate nanocatalysts present advantages to trigger a continuous
macular degeneration in an animal model through a catalytic ROS-scavenging effect in the retina. Chen et al.
single intravitreal injection. Very recently, Nguyen et first reported that CeO nanoparticles can prevent retinal
362
2
al. have encapsulated resveratrol in a polycaprolactone degeneration after intravitreal administration in a light-
nanoparticle to scavenge excessive ROS in retina and damage rat model. Mitra et al. used glycol chitosan to
364
mitigate inflammation (Figure 24). In this work, modify the surface of CeO nanoparticles, improving
363
2
metformin with antiangiogenic effect was also engineered the solubility and biocompatibility of this antioxidative
on the nanomedicine, synergistically favoring AMD nanocatalyst, favorable for AMD treatment. Badia et al.
365
treatment. The therapeutic effect of the nanomedicine can further prepared an eye drop solution containing CeO
2

Figure 24. Schematic illustration for the administration and retinal permeation of resveratrol-loaded nanomedicine, as well as its application in age-related
macular degeneration therapy. Reproduced with permission from Nguyen et al. Copyright © 2022, American Chemical Society.
363

Volume 1 Issue 1 (2024) 30 doi: 10.36922/imo.2527